Key statistics
On Monday, Stoke Therapeutics Inc (STOK:NSQ) closed at 11.40, -35.15% below its 52-week high of 17.58, set on Jun 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.78 |
---|---|
High | 11.78 |
Low | 11.15 |
Bid | 10.00 |
Offer | 12.67 |
Previous close | 11.79 |
Average volume | 620.66k |
---|---|
Shares outstanding | 52.65m |
Free float | 50.27m |
P/E (TTM) | -- |
Market cap | 620.72m USD |
EPS (TTM) | -2.18 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 21:00 BST.
More ▼
Press releases
- Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
- Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
- Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
- Stoke Therapeutics to Present at Upcoming Investor Conferences in September
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
More ▼